Sign in
Taking people in NetherlandsPhase 4

Tests mepolizumab in adults with eosinophilic granulomatosis with polyangiitis

Studies how mepolizumab affects nasal bacteria and immune response in eosinophilic granulomatosis with polyangiitis.

Key facts

Who runs it
Universitair Medisch Centrum Groningen
Where
Groningen, NetherlandsSee the site
Registry title
eGPA and local inflammation within the ENT area
Status
Recruiting
Phase
Phase 4
People taking part
150 people, planned
Started
13 Feb 2024
Expected to end
1 Dec 2027
Type of study
Interventional
Record updated
2 February 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with eGPA, and also adults with GPA, severe asthma or nasal polyps, and healthy controls.

Age
Older than 18 years.
Sex
All sexes can join.
Disease stage
Each group has its own disease requirement. eGPA group: meets the 2022 ACR/EULAR criteria for eGPA. GPA group: meets the ACR/EULAR GPA criteria. Nasal polyp group: polyps on both sides of the nose seen by endoscopy or CT scan. Severe asthma group: clinical asthma with FEV1 below 80% and either reversibility of more than 12% or a positive metacholine challenge (PC20 below 8 mg/ml). Healthy group: no asthma symptoms and no bronchial hyperresponsiveness.
Earlier treatment
Healthy controls cannot have used immunosuppressive medication or local anti-inflammatory agents long-term, or antibiotics in the last month. Nobody can have used dupilumab within 6 months before the baseline visit. Nasal polyp group: no current asthma medication.

Main reasons for not taking part

  • Cannot give informed consent
  • Active smoking less than 6 months before the baseline visit
  • Pregnant or breastfeeding women
  • Use of dupilumab within 6 months of the baseline visit
  • Nasal polyp group: current use of asthma medication, or eGPA

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • >18 years of age
  • Able to give informed consent
  • In CRSwNP group: availability of bilateral nasal polyps as diagnosed by endoscopy or CT scan
  • In Severe asthma group: clinical diagnosis of asthma with FEV1 <80% AND either FEV1 reversibility >12% initial or documented positive metacholine challenge (PC20 < 8 mg/ml)
  • In eGPA group: Fulfilling the 2022 ACR/EULAR criteria for eGPA (Wechsler et al., 2017)
  • In GPA group: fulfilling the ACR/EULAR GPA criteria (Robson et al., 2022)
  • In healthy controls: absence of asthma symptoms, no bronchial hyperresponsiveness

Who cannot take part

  • In CRSwNP group: current use of asthma medication, eGPA
  • In healthy controls: use of immunosuppressive medication
  • concomitant use of dupilumab within 6 months of baseline visit
  • Unable to give informed consent
  • Active smoking < (less than) 6 months from baseline visit
  • Pregnant or breastfeeding woman
  • In healthy controls: chronic use of local anti-inflammtory agents
  • In healthy controls: use of antibiotics within the last month (before start study/screening/)

Where in Netherlands

  • Universitair Medisch Centrum GroningenGroningen, NetherlandsTaking people

About the trial

What the trial wants to find out

In eGPA patients treatment with mepolizumab restores changes of the nasal microbiome healthy control phenotype

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
eGPA and local inflammation within the ENT area; Impact of Mepolizumab treatment on the nasal microbiome and local and systemic immune response in eosinophilic granulomatosis with polyangitis (eGPA)
Plain-language title
Tests mepolizumab in adults with eosinophilic granulomatosis with polyangiitisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
2 February 2024